Aarti Drugs Q3FY25 results: Net profit at ₹37 crore, revenue at ₹556 crore

Aarti Drugs has reported its financial results for the third quarter of FY25, showing a modest increase in net profit despite a decline in revenue. The company’s consolidated net profit rose 1.1% year-over-year (YoY) to ₹37.1 crore, compared to ₹36.7 crore in the same period last year. However, revenue declined by 8.1% YoY to ₹556.6 crore, down from ₹605.9 crore.

Earnings before interest, taxes, depreciation, and amortization (EBITDA) dropped 11.8% YoY to ₹61.8 crore, compared to ₹70.1 crore in the previous year. The EBITDA margin declined slightly to 11.1% from 11.6% YoY.

Aarti Drugs also announced an interim dividend of ₹1 per share, with February 4, 2025, set as the record date for eligible shareholders.

“We wish to inform you that the Board of Directors, at its meeting on January 29, 2025, declared an interim dividend of ₹1 per equity share (10%) for FY25. As per SEBI (LODR) Regulations, the record date for the dividend is February 4, 2025,” the company stated in an exchange filing.

Also Watch | Adhish Patil, CFO of Aarti Drugsdiscusses the October-December 2024 (Q3FY25) figures in an interview with CNBC-TV18.

Shares of Aarti Drugs rose nearly 2% to ₹397.40 apiece on the NSE. However, the stock has corrected by over 21% in the past year.